ProShare Advisors’s Day One Biopharmaceuticals DAWN Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $121K | Buy |
18,545
+2,121
| +13% | +$13.8K | ﹤0.01% | 1840 |
|
|
2025
Q1 | $130K | Sell |
16,424
-2,970
| -15% | -$23.6K | ﹤0.01% | 1781 |
|
|
2024
Q4 | $246K | Buy |
19,394
+3,687
| +23% | +$46.7K | ﹤0.01% | 1770 |
|
|
2024
Q3 | $219K | Buy |
15,707
+1,920
| +14% | +$26.7K | ﹤0.01% | 1673 |
|
|
2024
Q2 | $190K | Sell |
13,787
-3,592
| -21% | -$49.5K | ﹤0.01% | 1542 |
|
|
2024
Q1 | $287K | Buy |
17,379
+1,447
| +9% | +$23.9K | ﹤0.01% | 1451 |
|
|
2023
Q4 | $233K | Buy |
15,932
+2,108
| +15% | +$30.8K | ﹤0.01% | 1555 |
|
|
2023
Q3 | $170K | Buy |
13,824
+2,660
| +24% | +$32.6K | ﹤0.01% | 1515 |
|
|
2023
Q2 | $133K | Buy |
+11,164
| New | +$133K | ﹤0.01% | 1643 |
|
|
2023
Q1 | – | Sell |
-9,645
| Closed | -$208K | – | 1819 |
|
|
2022
Q4 | $208K | Buy |
+9,645
| New | +$208K | ﹤0.01% | 1468 |
|
|
2022
Q2 | – | Sell |
-10,675
| Closed | -$106K | – | 1872 |
|
|
2022
Q1 | $106K | Sell |
10,675
-452
| -4% | -$4.49K | ﹤0.01% | 2016 |
|
|
2021
Q4 | $188K | Buy |
+11,127
| New | +$188K | ﹤0.01% | 2052 |
|